Trial Profile
Multi-Center, Randomized, Open, Phase II Study to Evaluate Efficacy and Safety in Chemotherapy-induced Neutropenia of Once-per-cycle DA-3031(PEG-G-CSF) and Daily G-CSF in Patients With Malignancies Receiving Myelosuppressive Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary) ; Filgrastim
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Dong-A Pharmaceutical
- 14 May 2014 New trial record